Skip to content
Home
Rakesh K. Singh, Ph.D., M.Phil.

Rakesh K. Singh, Ph.D., M.Phil.

Contact

Office (585) 276-6281

About Me

Like thousands of medicinal chemists across the world I frequently spin my magnetic bars overnight, scratch round bottom flasks next morning as if the molecules are hiding somewhere in the flask walls and look at my harvest anxiously standing around my dirty and disorganized chemical hood hoping tha...
Like thousands of medicinal chemists across the world I frequently spin my magnetic bars overnight, scratch round bottom flasks next morning as if the molecules are hiding somewhere in the flask walls and look at my harvest anxiously standing around my dirty and disorganized chemical hood hoping that NMR and Mass will be okay and my hunt for that elusive molecule which is going to help someone rid of his/her disease to some extent is finally complete. In this tryst, I combine alphabets of cancer biology, tumor immunology, medicinal chemistry and some rudimentary pharmacology and drug design concepts and in vitro and in vivo models of tumors for screening; and seek guidance from molecular modeling/virtual screening experts and most recently with some extraterrestrial artificial intelligence (AI) nerds to design a drug-like molecule against a protein target which physicians or researchers believe has gone awry (based on their trust in p values) and is making some one sick.

Faculty Appointments

Research Associate Professor - Department of Obstetrics and Gynecology (SMD)

Credentials

Education

PhD | India-Jamia Millia Islamia-Delhi. Medicinal Chemistry. 2003

M.Phil | India-Birla Institute of Tech and Science. Medicinal Chemistry. 1996

Awards

Ranbaxy Research Fellowship. 1999 - 2001

Senior Research Fellowship. 1997 - 1998

Research

In team with renowned physicians, immunologists, cancer biologists and molecular modelling colleagues sitting in different continents and those extraterrestrial AI nerds situated somewhere on the west coast I currently focus on developing small molecule based immunotherapeutics for treatment of high...
In team with renowned physicians, immunologists, cancer biologists and molecular modelling colleagues sitting in different continents and those extraterrestrial AI nerds situated somewhere on the west coast I currently focus on developing small molecule based immunotherapeutics for treatment of high-risk malignancies such as but not limited to:

• Ovarian cancer
• Neuroblastoma
• Medulloblastoma
• Pancreatic cancer
• Melanoma
• Colorectal cancer

Complexities of drug-discovery commerce aside, small molecule based immunotherapeutics can be a viable alternative or a great complementary armamentarium to antibody based immunotherapies for treatment of high-risk malignancies or diseases.

Patents

Derivatives of Vitamin D and Therapeutic Use Thereof

Issue date: May 11, 2011

Patent #: 1968383

Country: Europe

Inventors: Laurent Brard, Satyan Kalkunte, Rakesh K Singh

Heterocycles and Derivatives Thereof and Methods of Manufacture and Therapeutic Use

Issue date: May 05, 2015

Patent #: 9,024,039

Country: United States

Inventors: Laurent Brard, Satyan Kalkunte, Rakesh K Singh

N-Amino Tetrahydrothiazine Derivatives, Methods of Manufacture and Use

Issue date: August 11, 2015

Patent #: 2,676,527

Country: Canada

Inventors: Laurent Brard, Kyu Kwang Kim, Giselle Saulnier-Sholler, Rakesh K Singh

N-Amino Tetrahydrothiazine Derivatives, Methods of Manufacture and Use

Issue date: March 25, 2015

Patent #: 2114410

Country: Europe

Inventors: Laurent Brard, Kyu Kwang Kim, Giselle Saulnier-Sholler, Rakesh K Singh

N-Amino Tetrahydrothiazine Derivatives, Methods of Manufacture and Use

Issue date: June 05, 2012

Patent #: 8,193,180

Country: United States

Inventors: Laurent Brard, Kyu Kwang Kim, Giselle Saulnier-Sholler, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: 3128996

Country: Europe

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: May 29, 2018

Patent #: 9,982,010

Country: United States

Inventors: Richard G Moore, Rakesh K Singh

Therapy for Malignant Disease Comprising the Inhibition of Human Epididymal Secretory Protein E4 and Immune Checkpoint Inhibitors

Issue date: December 14, 2021

Patent #: 2,981,068

Country: Canada

Inventors: Richard G Moore, Rakesh K Singh, Naohiro Yano

Therapy for Malignant Disease

Issue date: August 13, 2019

Patent #: 10,376,535

Country: United States

Inventors: Richard G Moore, Rakesh K Singh, Naohiro Yano

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: 3311165

Country: Europe

Inventors: Richard G Moore, Rakesh K Singh

Derivatives of Vitamin D and Therapeutic Use Thereof

Issue date: May 11, 2011

Patent #: FR1968383

Country: France

Inventors: Laurent Brard, Satyan Kalkunte, Rakesh K Singh

Derivatives of Vitamin D and Therapeutic Use Thereof

Issue date: May 11, 2011

Patent #: DE1968383

Country: Germany

Inventors: Laurent Brard, Satyan Kalkunte, Rakesh K Singh

N-Amino Tetrahydrothiazine Derivatives, Methods of Manufacture and Use

Issue date: March 25, 2015

Patent #: FR2114410

Country: France

Inventors: Laurent Brard, Kyu Kwang Kim, Giselle Saulnier-Sholler, Rakesh K Singh

7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 16, 2020

Patent #: 10,683,324

Country: United States

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 15, 2021

Patent #: 11,034,719

Country: United States

Inventors: Richard G Moore, Rakesh K Singh

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: FR3311165

Country: France

Inventors: Richard G Moore, Rakesh K Singh

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: DE3311165

Country: Germany

Inventors: Richard G Moore, Rakesh K Singh

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: GB3311165

Country: United Kingdom

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: FR3128996

Country: France

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: DE3128996

Country: Germany

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: GB3128996

Country: United Kingdom

Inventors: Richard G Moore, Rakesh K Singh

Publications

Journal Articles

Dysregulation of septin cytoskeletal organization in the trabecular meshwork contributes to ocular hypertension.

Maddala R, Gorijavolu P, Lankford LK, Skiba NP, Challa P, Singh RK, Nair KS, Choquet H, Rao PV

JCI insight.. 2024 December 69 (23)Epub 12/06/2024.

Author Correction: AI is a viable alternative to high throughput screening: a 318-target study.

Scientific reports.. 2024 September 1614 (1):21579. Epub 09/16/2024.

In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia.

Sahasrabudhe DM, Liesveld JL, Minhajuddin M, Singh NA, Nath S, Kumar VM, Balys M, Evans AG, Azadniv M, Hansen JN, Becker MW, Sharon A, Thomas VK, Moore RG, Khera MK, Jordan CT, Singh RK

Scientific reports.. 2024 June 414 (1):12868. Epub 06/04/2024.

AI is a viable alternative to high throughput screening: a 318-target study.

Scientific reports.. 2024 April 214 (1):7526. Epub 04/02/2024.

Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer.

Kim K, Khazan N, Rowswell-Turner RB, Singh RK, Moore T, Strawderman MS, Miller JP, Snyder CWA, Awada A, Moore RG

Cancers.. 2024 February 2816 (5)Epub 02/28/2024.

Septins provide microenvironment sensing and cortical actomyosin partitioning in motile amoeboid T lymphocytes.

Zhovmer AS, Manning A, Smith C, Nguyen A, Prince O, Sáez PJ, Ma X, Tsygankov D, Cartagena-Rivera AX, Singh NA, Singh RK, Tabdanov ED

Science advances.. 2024 January 510 (1):eadi1788. Epub 01/03/2024.

The NF-?B-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.

Kim K, Khazan N, McDowell JL, Snyder CWA, Miller JP, Singh RK, Whittum ME, Turner R, Moore RG

PloS one.. 2024 19 (12):e0314564. Epub 12/02/2024.

Dynein-Powered Cell Locomotion Guides Metastasis of Breast Cancer.

Tagay Y, Kheirabadi S, Ataie Z, Singh RK, Prince O, Nguyen A, Zhovmer AS, Ma X, Sheikhi A, Tsygankov D, Tabdanov ED

Advanced science.. 2023 November 10 (31):e2302229. Epub 09/19/2023.

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.

Khazan N, Quarato ER, Singh NA, Snyder CWA, Moore T, Miller JP, Yasui M, Teramoto Y, Goto T, Reshi S, Hong J, Zhang N, Pandey D, Srivastava P, Morell A, Kawano H, Kawano Y, Conley T, Sahasrabudhe DM, Yano N, Miyamoto H, Aljitawi O, Liesveld J, Becker MW, Calvi LM, Zhovmer AS, Tabdanov ED, Dokholyan NV, Linehan DC, Hansen JN, Gerber SA, Sharon A, Khera MK, Jurutka PW, Rochel N, Kim KK, Rowswell-Turner RB, Singh RK, Moore RG

Cancers.. 2023 June 3015 (13)Epub 06/30/2023.

Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors .

Khazan N, Kim KK, Hansen JN, Singh NA, Moore T, Snyder CWA, Pandita R, Strawderman M, Fujihara M, Takamura Y, Jian Y, Battaglia N, Yano N, Teramoto Y, Arnold LA, Hopson R, Kishor K, Nayak S, Ojha D, Sharon A, Ashton JM, Wang J, Milano MT, Miyamoto H, Linehan DC, Gerber SA, Kawar N, Singh AP, Tabdanov ED, Dokholyan NV, Kakuta H, Jurutka PW, Schor NF, Rowswell-Turner RB, Singh RK, Moore RG

Journal of medicinal chemistry.. 2022 April 2865 (8):6039-6055. Epub 04/11/2022.

Mechanical Counterbalance of Kinesin and Dynein Motors in a Microtubular Network Regulates Cell Mechanics, 3D Architecture, and Mechanosensing.

Zhovmer AS, Manning A, Smith C, Hayes JB, Burnette DT, Wang J, Cartagena-Rivera AX, Dokholyan NV, Singh RK, Tabdanov ED

ACS nano.. 2021 November 2315 (11):17528-17548. Epub 10/22/2021.

HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.

Rowswell-Turner RB, Singh RK, Urh A, Yano N, Kim KK, Khazan N, Pandita R, Sivagnanalingam U, Hovanesian V, James NE, Ribeiro JR, Kadambi S, Linehan DC, Moore RG

The Journal of immunology : official journal of the American Association of Immunologists.. 2021 May 15206 (10):2478-2488. Epub 04/26/2021.

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

James NE, Emerson JB, Borgstadt AD, Beffa L, Oliver MT, Hovanesian V, Urh A, Singh RK, Rowswell-Turner R, DiSilvestro PA, Ou J, Moore RG, Ribeiro JR

Scientific reports.. 2020 May 2210 (1):8558. Epub 05/22/2020.

Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines.

Kim KK, Singh RK, Khazan N, Kodza A, Singh NA, Jones A, Sivagnanalingam U, Towner M, Itamochi H, Turner R, Moore RG

Scientific reports.. 2020 February 2410 (1):3241. Epub 02/24/2020.

Role of trypsin and protease-activated receptor-2 in ovarian cancer.

Kim KK, Turner R, Khazan N, Kodza A, Jones A, Singh RK, Moore RG

PloS one.. 2020 15 (5):e0232253. Epub 05/04/2020.

Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.

Rowswell-Turner RB, Rutishauser JA, Kim KK, Khazan N, Sivagnanalingam U, Jones AM, Singh RK, Moore RG

Translational oncology.. 2019 July 12 (7):917-924. Epub 05/10/2019.

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.

James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC

Frontiers in pharmacology.. 2019 10 :216. Epub 03/19/2019.

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells.

James NE, Cantillo E, Oliver MT, Rowswell-Turner RB, Ribeiro JR, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC

Clinical and experimental immunology.. 2018 September 193 (3):327-340. Epub 1900 01 01.

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.

Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG

Journal of ovarian research.. 2016 May 179 (1):28. Epub 05/17/2016.

Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.

Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK, Moore RG

Scientific reports.. 2015 November 165 :15911. Epub 11/16/2015.

Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1? in cancer cells.

Kim KK, Abelman S, Yano N, Ribeiro JR, Singh RK, Tipping M, Moore RG

Scientific reports.. 2015 October 155 :14296. Epub 10/15/2015.

The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.

Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, Singh AP, Vorsa N

International journal of oncology.. 2015 May 46 (5):1924-34. Epub 03/17/2015.

Anticancer activity of VDR-coregulator inhibitor PS121912.

Sidhu PS, Teske K, Feleke B, Yuan NY, Guthrie ML, Fernstrum GB, Vyas ND, Han L, Preston J, Bogart JW, Silvaggi NR, Cook JM, Singh RK, Bikle DD, Arnold LA

Cancer chemotherapy and pharmacology.. 2014 October 74 (4):787-98. Epub 08/09/2014.

HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation.

Lokich E, Singh RK, Han A, Romano N, Yano N, Kim K, Moore RG

Scientific reports.. 2014 June 304 :5500. Epub 06/30/2014.

Development of novel Vitamin D Receptor-Coactivator Inhibitors.

Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA

ACS medicinal chemistry letters.. 2014 February 135 (2):199-204. Epub 1900 01 01.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK

Scientific reports.. 2014 January 64 :3574. Epub 01/06/2014.

IDENTIFICATION OF VDR ANTAGONISTS AMONG NUCLEAR RECEPTOR LIGANDS USING VIRTUAL SCREENING.

Teske K, Nandhikonda P, Bogart JW, Feleke B, Sidhu P, Yuan N, Preston J, Goy R, Han L, Silvaggi NR, Singh RK, Bikle DD, Cook JM, Arnold LA

Nuclear receptor research.. 2014 1 Epub 1900 01 01.

PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models.

Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KA, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, Brard L, Singh RK

Genes & cancer.. 2013 November 4 (11-12):524-34. Epub 1900 01 01.

7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells.

Kristjansdottir K, Kim K, Choi JS, Horan TC, Brard L, Moore RG, Singh RK

Gynecologic oncology.. 2012 August 126 (2):252-8. Epub 05/02/2012.

Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.

Kim KK, Lange TS, Singh RK, Brard L, Moore RG

BMC cancer.. 2012 April 1312 :147. Epub 04/13/2012.

Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells.

Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG

International journal of oncology.. 2012 January 40 (1):227-35. Epub 09/12/2011.

Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells.

Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK

Chemical biology & drug design.. 2012 January 79 (1):92-103. Epub 11/04/2011.

Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells.

Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N, Singh RK

International journal of oncology.. 2012 January 40 (1):99-108. Epub 10/06/2011.

Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK

PloS one.. 2012 7 (4):e34443. Epub 04/03/2012.

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.

Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK

Gynecologic oncology.. 2011 November 123 (2):370-8. Epub 07/30/2011.

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS

BMC cancer.. 2011 July 2211 :308. Epub 07/22/2011.

Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.

Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG

Gynecologic oncology.. 2011 July 122 (1):183-9. Epub 05/06/2011.

Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro.

Singh RK, Dorf L, DeMartino A, Illenye S, Koto K, Currier EA, Ashikaga T, Kim KK, Brard L, Sholler GL

Cancer biology & therapy.. 2011 June 1511 (12):1036-45. Epub 06/15/2011.

Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma.

Koto KS, Lescault P, Brard L, Kim K, Singh RK, Bond J, Illenye S, Slavik MA, Ashikaga T, Saulnier Sholler GL

International journal of oncology.. 2011 May 38 (5):1329-41. Epub 03/10/2011.

Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation.

Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS

PloS one.. 2011 April 296 (4):e19049. Epub 04/29/2011.

A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.

Singh RK, Lange TS, Kim KK, Brard L

Investigational new drugs.. 2011 February 29 (1):63-72. Epub 10/29/2009.

Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model.

Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA, Brard L

Investigational new drugs.. 2010 October 28 (5):543-53. Epub 07/07/2009.

Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model.

Lange TS, Zou Y, Singh RK, Kim KK, Kristjansdottir K, Sholler GL, Brard L

Chemical biology & drug design.. 2010 August 76 (2):164-73. Epub 05/11/2010.

Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Kim KK, Lange TS, Singh RK, Brard L

BMC cancer.. 2010 February 2510 :72. Epub 02/25/2010.

Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model.

Lange TS, McCourt C, Singh RK, Kim KK, Singh AP, Luisi BS, Alptürk O, Strongin RM, Brard L

Drug design, development and therapy.. 2009 September 213 :17-26. Epub 09/21/2009.

Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinum-resistant ovarian cancer cells to paraplatin.

Singh AP, Singh RK, Kim KK, Satyan KS, Nussbaum R, Torres M, Brard L, Vorsa N

Phytotherapy research : PTR.. 2009 August 23 (8):1066-74. Epub 1900 01 01.

Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells.

Brard L, Singh RK, Kim KK, Lange TS, Sholler GL

Drug design, development and therapy.. 2009 February 62 :61-9. Epub 02/06/2009.

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells.

Singh RK, Lange TS, Kim KK, Singh AP, Vorsa N, Brard L

British journal of cancer.. 2008 December 299 (11):1823-31. Epub 11/11/2008.

Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.

Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L

PloS one.. 2008 May 283 (5):e2303. Epub 05/28/2008.

A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.

Singh RK, Lange TS, Kim KK, Shaw SK, Brard L

Gynecologic oncology.. 2008 May 109 (2):240-9. Epub 03/07/2008.

RKS-2-62: A novel therapy for medulloblastoma with activity in vitro and in vivo.

Koto K, Brard L, Bosenberg M, Singh RK, Kim KK. Scholler GS.

Neurooncology. 2008; 10: 513-514.

Synthesis of Bicyclic Aryl Thiazolines with selective anti-proliferative effects on human cancer cell lines.

Singh RK, Lange TS, Kim KK, Singh AP, Hopson R, Vorsa N, Brard L.

Lett Org Chem. 2008; 5: 103-109.

Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines.

Singh RK, Lange TS, Kim K, Zou Y, Lieb C, Sholler GL, Brard L

Bioorganic & medicinal chemistry letters.. 2007 November 117 (21):5846-52. Epub 08/19/2007.

Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma.

Lange TS, Singh RK, Kim KK, Zou Y, Kalkunte SS, Sholler GL, Swamy N, Brard L

Chemical biology & drug design.. 2007 October 70 (4):302-10. Epub 1900 01 01.

A simple and efficient synthesis of 8-methyl-3, 8-diazabicyclo[3.2.1]octane (azatropane) and 3-substituted azatropanes therefrom using pyroglutamic acid.

Singh RK, Jain S, Sinha N, Mehta A, Naqvi F, Agarwal AK and Anand N.

Tet Lett. 2007; 48: 545-548.

Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation.

Satyan KS, Swamy N, Dizon DS, Singh R, Granai CO, Brard L

Gynecologic oncology.. 2006 October 103 (1):261-70. Epub 04/19/2006.

A general and efficient sythesis of 3,6-diazabicyclo[3.2.1]octanes.

Singh RK, Sinha N, Jain S, Naqvi F, Mehta A.

Tetrahedron. 2006; 62: 4011-4017.

Synthesis of optically active heterocyclic alpha-amino acids from activated lactams.

Singh RK, Sinha N, Jain S, Naqvi F, Salman M. and Anand N.

Part-1. Synthesis. 2005; 16: 2765-2771.

Synthesis of optically active beta-heterocyclic beta-amino acids from activated lactam.

Singh RK, Sinha N, Jain S, Naqvi F, Anand N.

Part-2. Tetrahedron. 2005; 61(37): 8868-8874.